114 related articles for article (PubMed ID: 37994899)
21. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
[TBL] [Abstract][Full Text] [Related]
22. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of O-GlcNAc Transferase Alters the Differentiation and Maturation Process of Human Monocyte Derived Dendritic Cells.
Weiss M; Anderluh M; Gobec M
Cells; 2021 Nov; 10(12):. PubMed ID: 34943826
[TBL] [Abstract][Full Text] [Related]
24. High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate.
Zhou P; Chang WY; Gong DA; Xia J; Chen W; Huang LY; Liu R; Liu Y; Chen C; Wang K; Tang N; Huang AL
Cell Metab; 2023 Nov; 35(11):1961-1975.e6. PubMed ID: 37797623
[TBL] [Abstract][Full Text] [Related]
25. High OGT activity is essential for MYC-driven proliferation of prostate cancer cells.
Itkonen HM; Urbanucci A; Martin SE; Khan A; Mathelier A; Thiede B; Walker S; Mills IG
Theranostics; 2019; 9(8):2183-2197. PubMed ID: 31149037
[TBL] [Abstract][Full Text] [Related]
26. Synergistic apoptosis by combination of metformin and an O-GlcNAcylation inhibitor in colon cancer cells.
Lee DE; Lee GY; Lee HM; Choi SY; Lee SJ; Kwon OS
Cancer Cell Int; 2023 Jun; 23(1):108. PubMed ID: 37268905
[TBL] [Abstract][Full Text] [Related]
27. The role of O-GlcNAcylation mediated by OGT during tooth development.
Pokharel E; Aryal YP; Kim TY; Kim A; Jung JK; An SY; Kwon TY; Min BK; Yamamoto H; Cho SW; Sohn WJ; An CH; Lee Y; Kim DY; Ha JH; Kim JY
J Cell Physiol; 2023 Jul; 238(7):1520-1529. PubMed ID: 37098720
[TBL] [Abstract][Full Text] [Related]
28. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation.
Ding H; Liu J; Zou R; Cheng P; Su Y
J Exp Clin Cancer Res; 2019 May; 38(1):189. PubMed ID: 31072375
[TBL] [Abstract][Full Text] [Related]
29. Sialic acid-decorated liposomes enhance the anti-cancer efficacy of docetaxel in tumor-associated macrophages.
Tran NP; Tran P; Yoo SY; Tangchang W; Lee S; Lee JY; Son HY; Park JS
Biomater Adv; 2023 Nov; 154():213606. PubMed ID: 37678087
[TBL] [Abstract][Full Text] [Related]
30. Investigating the Impact of OGT Inhibition on Doxorubicin- and Docetaxel-Induced Cytotoxicity in PC-3 and WPMY-1 Cells.
Makwana V; Dukie AS; Rudrawar S
Int J Toxicol; 2020; 39(6):586-593. PubMed ID: 32851890
[TBL] [Abstract][Full Text] [Related]
31. O-GlcNAcylation of RAB10 promotes hepatocellular carcinoma progression.
Lv Z; Ma G; Zhong Z; Xie X; Li B; Long D
Carcinogenesis; 2023 Dec; 44(10-11):785-794. PubMed ID: 37218374
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
33. Hyper-O-GlcNAcylation of YB-1 affects Ser102 phosphorylation and promotes cell proliferation in hepatocellular carcinoma.
Liu Q; Tao T; Liu F; Ni R; Lu C; Shen A
Exp Cell Res; 2016 Dec; 349(2):230-238. PubMed ID: 27751836
[TBL] [Abstract][Full Text] [Related]
34. The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate.
She Z; Zhang T; Wang X; Li X; Song Y; Cheng X; Huang Z; Deng Y
Biomaterials; 2014 Jun; 35(19):5216-25. PubMed ID: 24703714
[TBL] [Abstract][Full Text] [Related]
35. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
[TBL] [Abstract][Full Text] [Related]
36. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
[TBL] [Abstract][Full Text] [Related]
37. Chromatin-associated OGT promotes the malignant progression of hepatocellular carcinoma by activating ZNF263.
Wang L; Li G; Zhou Z; Ge C; Chen Q; Liu Y; Zhang N; Zhang K; Niu M; Li W; Zhong X; Wu S; Zhang J; Liu Y
Oncogene; 2023 Jul; 42(30):2329-2346. PubMed ID: 37353617
[TBL] [Abstract][Full Text] [Related]
38. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
[TBL] [Abstract][Full Text] [Related]
39. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
[TBL] [Abstract][Full Text] [Related]
40. Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy.
Ding J; Zhao D; Hu Y; Liu M; Liao X; Zhao B; Liu X; Deng Y; Song Y
Int J Pharm; 2019 Nov; 571():118706. PubMed ID: 31593811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
